SCHEMBL25035486

SCHEMBL25035486

CC(C)n1c(=O)c(-c2ccc(NS(=O)(=O)c3cccnc3)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.43
PI4KA P42356 3/20 0.42
PIK3CG P48736 3/20 0.42
ABCB1 P08183 1/20 0.42
ABCC1 P33527 1/20 0.42
SLC40A1 Q9NP59 4/20 0.40
PIK3CA P42336 1/20 0.40
MTOR P42345 1/20 0.40
LMNA P02545 1/20 0.39
GLO1 Q04760 1/20 0.39
BRAF P15056 3/20 0.38
KIT P10721 2/20 0.38
BRD4 O60885 1/20 0.37
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
MAP2K7 O14733 1/20 0.36
MAP2K4 P45985 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25035568 0.92 ERN1 (0.45) ERN1PI4KAPIK3CGLMNABRAF
SCHEMBL25035440 0.84 ERN1 (0.48) ERN1PI4KAPIK3CGPIK3CAKIT
SCHEMBL25035485 0.83 ERN1 (0.48) ERN1PI4KAPIK3CGMTORLMNA
SCHEMBL22200598 0.83 ERN1 (0.38) ERN1ABCB1MTOR
SCHEMBL25035356 0.83 ERN1 (0.49) ERN1PI4KAPIK3CGSLC40A1PIK3CA
SCHEMBL22200313 0.82 ERN1 (0.58) ERN1PI4KAPIK3CGABCB1ABCC1
SCHEMBL25035427 0.82 BRAF (0.51) ERN1BRAFKITALOX5APFEN1
Hydrochloric Acid SCHEMBL22191317 0.82 ERN1 (0.58) ERN1PI4KAPIK3CGABCB1ABCC1
Hydrochloric Acid SCHEMBL22191315 0.82 ERN1 (0.58) ERN1PI4KAPIK3CGABCB1ABCC1
Hydrochloric Acid SCHEMBL29356327 0.82 ERN1 (0.58) ERN1PI4KAPIK3CGABCB1ABCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE PARAZA PHARMA, INC. (CA) 2023-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE TYMP, TYMS, DPYD ERN1 3167/4885PI4KA 1151/4885PIK3CG 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.